Takeda Pharmaceutical (TAK) Change in Account Payables (2018 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Change in Account Payables of -$143.7 million for Q2 2026, up 25.13% year-over-year from -$114.9 million in Q2 2025, and down 569.71% quarter-over-quarter from $30.6 million in Q1 2026.
Takeda Pharmaceutical (TAK) Change in Account Payables (2018 - 2026) Analysis & Trends
Takeda Pharmaceutical's Change in Account Payables history runs 9 years deep, the most recent figure standing at -$143.7 million for Q2 2026.
- In Q2 2026, Change in Account Payables rose 25.13% year-over-year to -$143.7 million; the TTM figure through Jun 2026 stood at $20.5 million (up 178.28% YoY), while the FY2026 annual figure was -$20.9 million, up 55.22% from the prior year.
- Change in Account Payables for Q2 2026 stood at -$143.7 million, down from $30.6 million in the prior quarter.
- The five-year high for Change in Account Payables was $1.1 billion in Q1 2022, with the low at -$751.0 million in Q2 2022.
- The 5-year median for Change in Account Payables is -$26.0 million (2022), against an average of $8.4 million.
- The sharpest annual moves came in 2022 and 2025: Change in Account Payables slumped 302.34% in 2022, then soared 4352.61% in 2025.
- Takeda Pharmaceutical's Change in Account Payables stood at -$54.6 million in 2022, then soared by 970.94% to $475.4 million in 2023, then slumped by 72.84% to $129.1 million in 2024, then slumped by 83.43% to $21.4 million in 2025, then sank by 771.74% to -$143.7 million in 2026.
- Business Quant data shows TAK's Change in Account Payables at -$143.7 million in Q2 2026, $30.6 million in Q1 2026, and $21.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Alkermes | 8.17 Bn | 7.51 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -143.74 Mn |
| Jun 30, 2026 | -143.74 Mn |
| Mar 31, 2026 | 30.60 Mn |
| Mar 31, 2026 | 30.60 Mn |
| Dec 31, 2025 | 21.40 Mn |
| Dec 31, 2025 | 21.40 Mn |
| Sep 30, 2025 | 112.24 Mn |
| Sep 30, 2025 | 112.24 Mn |
| Jun 30, 2025 | -191.99 Mn |
| Jun 30, 2025 | -191.99 Mn |
| Mar 31, 2025 | 67.71 Mn |
| Mar 31, 2025 | 67.71 Mn |
| Dec 31, 2024 | 129.13 Mn |
| Dec 31, 2024 | 129.13 Mn |
| Sep 30, 2024 | 2.52 Mn |
| Sep 30, 2024 | 2.52 Mn |
| Jun 30, 2024 | -240.61 Mn |
| Jun 30, 2024 | -240.61 Mn |
| Mar 31, 2024 | -205.69 Mn |
| Mar 31, 2024 | -205.69 Mn |